Search | Clinical Trials Finder

Conditions: Coronary Artery Disease, Mild Cognitive Impairment, Obesity, Abdominal, Hypertension
Interventions: Metformin, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years to 79 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cannabis Use, Substance Use Disorder (SUD), Healthy
Interventions: Placebo Oral Capsule, THC; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 21 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: COVID-19
Interventions: nirmatrelvir, ritonavir, placebo for nirmatrelvir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 67
States / cities: Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 47 more

Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions: Tafamidis, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 50
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more

Conditions: Fibromyalgia
Interventions: Pregabalin, then placebo, Placebo, then pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Alcohol Use Disorder (AUD)
Interventions: oleoylethanolamide; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 25 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Amyloidosis
Interventions: KIACTA (eprodisate disodium), Placebo; Drug
Lead sponsor: C.T. Development America, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: Glendale, California • Boston, Massachusetts • Columbus, Ohio

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 19
States / cities: Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more

Conditions: Deficiency of Vitamin D3, COPD
Interventions: Cholecalciferol, multivitamin, Placebo; Dietary Supplement
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Peripheral Arterial Disease
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 40 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Major Depression
Interventions: Psilocybin (Usona Institute), Propofol, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 25 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: COVID19, COVID-19, COVID
Interventions: Pacritinib, Placebo; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 21
States / cities: Orange, California • Jacksonville, Florida • Atlanta, Georgia + 16 more

Conditions: Drug Safety
Interventions: Placebo, VIA-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Endometriosis Related Pain
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 41
States / cities: Andalusia, Alabama • Washington D.C., District of Columbia • Aventura, Florida + 36 more

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 23
States / cities: Phoenix, Arizona • Centennial, Colorado • Fort Collins, Colorado + 20 more

Conditions: Sickle Cell Disease, Sickle-Cell; Hb-SC, Sickle Beta 0 Thalassemia
Interventions: IMR-687, Placebo Oral Capsule; Drug
Lead sponsor: Cardurion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Lupus Nephritis
Interventions: Ixazomib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 12
States / cities: La Jolla, California • Upland, California • Port Charlotte, Florida + 9 more

Conditions: Breast Cancer
Interventions: Placebo, Valproic Acid (VPA), Questionnaires, Pill Diary, Drainage Diary; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alzheimer's Disease
Interventions: NGP 555; Drug
Lead sponsor: NeuroGenetic Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Pseudohypoparathyroidism, Albright Hereditary Osteodystrophy, Pseudohypoparathyroidism Type 1a
Interventions: Theophylline, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 2 Years to 12 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Major Depressive Disorder, Anxiety Disorders
Interventions: Hydrocortisone; Drug
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Austin, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, PF-04937319; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Phoenix, Arizona • Cypress, California • Miami, Florida

Conditions: Alport Syndrome
Interventions: Placebo Oral Capsule, Bardoxolone Methyl; Drug
Lead sponsor: Biogen; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more

Conditions: Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease
Interventions: Placebo Oral Capsule, NYX-458; Drug
Lead sponsor: Aptinyx; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 26
States / cities: Scottsdale, Arizona • Fresno, California • Simi Valley, California + 20 more

Search by objective public record fields.

Genomic Outcomes of Metformin

Research Investigating Drug Effects-2 (RiDE-2)

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

An fMRI Study Of Brain Response In Patients With Fibromyalgia

OEA for Young Adults With Alcohol Use Disorder

Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

The Pittsburgh Vitamin D Study: Vitamin D Supplementation in Vitamin D-deficient Subjects at Risk of Lung Cancer

Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities

Study of Psilocybin Under Anesthesia Controlled by EEG

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

A Study of IMR-687 in Healthy Adult Volunteers

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)

Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)

Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old

Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration

A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)